undamentalytics Newsletter
Sign in

Ensysce Biosciences, Inc. income statement

In fiscal 2025, Ensysce Biosciences, Inc. reported revenue of $5.1m, down 2.8% on the year before, operating income of −$10.2m (a -202.1% margin) and net income of −$10.2m, or −$3.98 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue4432555
Research and development4520871012
Selling, general and administrative119—————
General and administrative——75555
Operating income−2−20−24−11−7−10−13
Interest expense1100100
Provision for credit losses0−0−0−0———
Income before tax5——————
Income tax0——————
Net income4−30−25−11−8−10−13
Diluted EPS$0.00−$1.48−$139.42−$70.40−$11.45−$3.98—
Diluted shares (average)17m20m———3m—
EBITDA−2−20−24−11−7−10−13

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ENSC vs OCGNENSC vs TRDACRIS vs ENSCCAMP vs ENSC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ensysce Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ensysce Biosciences, Inc.